VERA vs. BBIO, LEGN, AXSM, BPMC, CYTK, NUVL, ELAN, LNTH, KRYS, and VRNA
Should you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Cytokinetics (CYTK), Nuvalent (NUVL), Elanco Animal Health (ELAN), Lantheus (LNTH), Krystal Biotech (KRYS), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry.
Vera Therapeutics vs.
BridgeBio Pharma (NASDAQ:BBIO) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.
Vera Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Vera Therapeutics' return on equity.
Vera Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.
BridgeBio Pharma presently has a consensus price target of $51.67, suggesting a potential upside of 56.52%. Vera Therapeutics has a consensus price target of $65.11, suggesting a potential upside of 129.18%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than BridgeBio Pharma.
BridgeBio Pharma received 133 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 71.78% of users gave BridgeBio Pharma an outperform vote while only 65.57% of users gave Vera Therapeutics an outperform vote.
99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 24.7% of BridgeBio Pharma shares are held by company insiders. Comparatively, 21.7% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, BridgeBio Pharma had 8 more articles in the media than Vera Therapeutics. MarketBeat recorded 30 mentions for BridgeBio Pharma and 22 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.87 beat BridgeBio Pharma's score of 0.77 indicating that Vera Therapeutics is being referred to more favorably in the news media.
BridgeBio Pharma has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
Summary
Vera Therapeutics beats BridgeBio Pharma on 10 of the 18 factors compared between the two stocks.
Get Vera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vera Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VERA) was last updated on 3/4/2025 by MarketBeat.com Staff
